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Summary
Background Incomplete vital registration systems mean that causes of death during pregnancy and childbirth are 
poorly understood in low-income and middle-income countries. To inform global efforts to reduce maternal mortality, 
we compared physician review and computerised analysis of verbal autopsies (interpreting verbal autopsies [InterVA] 
software), to understand their agreement on maternal cause of death and circumstances of mortality categories 
(COMCATs) in the Community-Level Interventions for Pre-eclampsia (CLIP) cluster randomised trials.
Methods The CLIP trials took place in India, Pakistan, and Mozambique, enrolling pregnant women aged 12–49 years 
between Nov 1, 2014, and Feb 28, 2017. 69 330 pregnant women were enrolled in 44 clusters (36 008 in the 
22 intervention clusters and 33 322 in the 22 control clusters). In this secondary analysis of maternal deaths in CLIP, 
we included women who died in any of the 22 intervention clusters or 22 control clusters. Trained staff administered 
the WHO 2012 verbal autopsy after maternal deaths. Two physicians (and a third for consensus, if needed) reviewed 
trial surveillance data and verbal autopsies, and, in intervention clusters, community health worker-led visit data. 
They determined cause of death according to the WHO International Classification of Diseases-Maternal Mortality 
(ICD-MM). Verbal autopsies were also analysed by InterVA computer models (versions 4 and 5) to generate cause of 
death. COMCAT analysis was provided by InterVA-5 and, in India, by physician review of Maternal Newborn Health 
Registry data. Causes of death and COMCATs assigned by physician review, Inter-VA-4, and InterVA-5 were compared, 
with agreement assessed with Cohen’s κ coefficient.
Findings Of 61 988 pregnancies with successful follow-up in the CLIP trials, 143 maternal deaths were reported 
(16 deaths in India, 105 in Pakistan, and 22 in Mozambique). The maternal death rate was 231 (95% CI 193–268) per 
100 000 identified pregnancies. Most deaths were attributed to direct maternal causes (rather than indirect or 
undetermined causes as per ICD-MM classification), with fair to good agreement between physician review and 
InterVA-4 (κ=0·56 [95% CI 0·43–0·66]) or InterVA-5 (κ=0·44 [0·30–0·57]), and InterVA-4 and InterVA-5 (κ=0·72 
[0·60–0·84]). The top three causes of death were the same by physician review, InterVA-4, and InterVA-5 (ICD-MM 
categories obstetric haemorrhage, non-obstetric complications, and hypertensive disorders); however, attribution of 
individual patient deaths to obstetric haemorrhage varied more between methods (physician review, 38 [27%] 
deaths; InterVA-4, 69 [48%] deaths; and InterVA-5, 82 [57%] deaths), than did attribution to non-obstetric causes 
(physician review, 39 [27%] deaths; InterVA-4, 37 [26%] deaths; and InterVA-5, 28 [20%] deaths) or hypertensive 
disorders (physician review, 23 [16%] deaths; InterVA-4, 25 [17%] deaths; and InterVA-5, 24 [17%] deaths). 
Agreement for all nine ICD-MM categories was fair for physician review versus InterVA-4 (κ=0·48 [0·38–0·58]), 
poor for physician review versus InterVA-5 (κ=0·36 [0·27–0·46]), and good for InterVA-4 versus InterVA-5 (κ=0·69 
[0·59–0·79]). The most commonly assigned COMCATs by InterVA-5 were emergencies (68 [48%] of 143 deaths) 
and health systems (62 [43%] deaths), and by physician review (India only) were health systems (seven [44%] of 
16 deaths) and inevitability (five [31%] deaths); agreement between InterVA-5 and physician review (India data only) 
was poor (κ=0·04 [0·00–0·15]).
Interpretation Our findings indicate that InterVA-5 is less accurate than InterVA-4 at ascertaining causes and 
circumstances of maternal death, when compared with physician review. Our results suggest a need to improve the 
next iteration of InterVA, and for researchers and clinicians to preferentially use InterVA-4 when recording maternal 
deaths.
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Introduction 
In 2015, more than 300 000 women died from compli­
cations during pregnancy or childbirth,1 mostly in low­
income and middle­income countries in sub­Saharan 
Africa and south Asia. Although the global maternal 
mortality rate (MMR) decreased during the Millennium 
Development Goal era (from 330 deaths per 100 000 live­
births in 2000 to 210 deaths per 100 000 in 2013),2 
achieving the Sustainable Development Goal MMR of 
fewer than 70 deaths per 100 000 livebirths by 2030 will 
require action by communities, health­care providers, 
and policy makers to address what underlies those deaths. 
However, the burden, timing, and ante cedents of 
maternal death are incompletely understood, largely due 
to a scarcity of comprehensive vital registration data.3
Various approaches have been developed to under stand 
the health­care journeys of women who have died during 
pregnancy or post partum. Physician review is effective in 
improving care and outcomes in settings where records 
are good and death occurs in health facilities (eg, the UK 
and Ireland4), but this approach is time consuming and 
challenged by incomplete documentation of all deaths, 
poor quality record keeping, and fear of retribution and 
legal action against those involved in the care of women 
who died. In settings where death registration is absent 
or incomplete, an alternative approach to understanding 
maternal deaths is verbal autopsy, a standardised 
interview with the deceased’s next of kin that is designed 
to explore the woman’s symp toms preceding her death, 
and the circumstances in which her death occurred. 
Computerised logarithmic probability models have been 
developed to analyse verbal autopsy responses, to 
establish reliable temporal and regional estimates of the 
probable cause of maternal death, with results that were 
similar to those obtained by physician review.5 The 
interpreting verbal autopsies (InterVA) probabilistic 
model was developed in 2012 by WHO, and is regularly 
updated to optimise accuracy in specific circumstances, 
such as maternal mortality.6
In particular, the hypertensive disorders of pregnancy 
and pre­eclampsia are recognised to be a leading cause of 
maternal mortality worldwide. The Community­Level 
Interventions for Pre­eclampsia (CLIP) cluster random­
ised controlled trials (RCTs) were designed to evaluate 
whether community engagement and community­level 
triage, transport, and treatment initiation could reduce 
all­cause maternal (and perinatal) deaths and morbidity, 
ascertained in the community, with maternal death 
evaluated with the WHO verbal autopsy questionnaire 
(2012 version).7 Although all­cause mortality in the CLIP 
trials did not differ between intervention and control 
clusters, in this secondary analysis we undertook 
physician review and InterVA assessments of all maternal 
deaths. Our aim was to compare agreement between 
physician review and InterVA methodologies with regard 
to cause of death and associated circumstances, to inform 
efforts for improving care.
Methods
CLIP trials design and participants
The CLIP trials were independent cluster RCTs in urban 
and rural India (12 clusters), Pakistan (20 clusters), 
Research in context
Evidence before this study
Based on our use of the 2012 WHO verbal autopsy and the 
publication date of the interpreting verbal autopsy model, 
version 4 (InterVA-4), we searched PubMed from Jan 1, 2012, 
to March 31, 2020 (updated on Oct 15, 2020), for publications 
on “maternal death” OR “maternal mortality” AND “verbal 
autopsy” AND “InterVA-4” OR “InterVA-5” OR “physician 
review”.  We limited our search to publications in English. We 
identified that, for maternal deaths, agreement on cause of 
death between physician review and computerised analysis of 
verbal autopsies with InterVA-4 has often, but not uniformly, 
been reported to be high, but usually with use of facility 
records, introducing a high risk of bias compared with 
population-level data.
Added value of this study
To our knowledge, this study is the first to specifically compare 
physician review with the InterVA-4 and InterVA-5 models for 
assignment of maternal cause of death. We also included the 
novel circumstances of mortality categories (COMCATs) 
component of InterVA-5 and compared these findings with 
COMCAT analysis by physician review. Although physician 
review and the InterVA-4 and InterVA-5 algorithms identified 
the same most common maternal causes of death (obstetric 
haemorrhage, non-obstetric complications, and hypertensive 
disorders), we found poor agreement between physician review 
and InterVA-5 on causes of death in individuals. The InterVA-5 
COMCAT results emphasise the importance of quality and 
continuity of care in facilities, which should be prioritised over 
care-seeking and transport to health facilities. Our findings are 
strengthened by a relatively large sample of maternal deaths, in 
urban and rural settings in south Asia and sub-Saharan Africa, 
and by use of data from communities with inadequate vital 
registration systems and the greatest need for computerised 
cause of death analysis of verbal autopsies.
Implications of all the available evidence
Our findings suggest that InterVA-4, and not InterVA-5, should 
be used to ascertain maternal cause of death and assist in 
reaching the WHO global standard of registering at least 50% of 
deaths in communities. Further work is required to refine the 
InterVA-5 cause of death and COMCAT analyses, and to identify 
opportunities for improving outcomes in pregnant and post-
partum women.
For more on InterVA see 
www.interva.net
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and Mozambique (12 clusters).7 Of the 44 clusters across 
the three trials, 22 were intervention clusters and 22 were 
control clusters.
In brief, pregnant women aged 15–49 years (12–49 years 
in Mozambique) were enrolled after confirmation of 
pregnancy and provision of informed consent, in India 
(Nov 1, 2014, to Oct 31, 2016), Pakistan (Jan 1, 2015, to 
Dec 31, 2016), and Mozambique (Feb 1, 2015, to 
Feb 28, 2017). In the three CLIP trials, 69 330 pregnant 
women were enrolled in 44 clusters (36 008 in the 
22 intervention clusters and 33 322 in the 22 control 
clusters), with successful follow­up for 61 988 (89%) preg­
nan cies.7 The intervention had two components: 
community engagement and clinical assessment by 
community health workers (mobile health­guided early 
detection); and initial treatment (ie, oral methyldopa for 
severe hypertension, and intramuscular magnesium 
sulphate for severe pre­eclampsia) and referral to a 
facility for hypertensive pregnancies. CLIP visits were 
recommended at least every 4 weeks before birth, and on 
post­partum days 3, 7, and 14. In control clusters, women 
received usual care according to local practice, stated to 
be blood pressure measurement and proteinuria testing 
at each antenatal care contact.
The primary outcome was a composite of maternal, 
fetal, and newborn death and severe morbidity; mortality 
was measured up to 6 weeks after birth for the mother 
and 28 days after birth for the neonate. Surveillance 
data were collected by cross­sectional household 
surveys (quarterly in Pakistan and every 6 months in 
Mozambique) or from the Global Network’s Maternal 
Newborn Health (MNH) Registry (in India).8 After 
obtaining individual informed consent, data were 
collected on baseline individual­level and household­level 
information, antenatal care, and adverse outcomes up to 
6 weeks after birth (for the mother) or 28 days after birth 
(for the neonate). Data collection tools were modified 
validated questionnaires translated into local languages. 
All maternal deaths (and perinatal deaths and maternal 
and neonatal morbidities) were confirmed by outcome 
adjudication of trial surveillance data, by in­country teams 
(primarily doctors) familiar with local language (for 
interpretation of narratives, if available) and context, but 
who were masked to cluster type and uninvolved in the 
women’s care. An independent trained team administered 
the WHO 2012 verbal autopsy9 as soon as possible after 
maternal death, by visiting the deceased woman’s 
household and interviewing a next of kin about health 
problems, symptoms, and circumstances in the time 
leading up to the woman’s death. In India, Mozambique, 
and some districts in Pakistan (those with the staffing 
capacity), interviewees asked next of kin at the end of the 
structured interview to describe in their own words what 
had happened to their loved one; these narratives were 
translated into English and used in physician review.
Data were entered on Android devices and de­identified, 
and transferred regularly to the University of British 
Columbia (UBC) CLIP coordinating centre (Vancouver, 
BC, Canada). Data were uploaded monthly onto the 
Research Electronic Data Capture server (version 5; 
Vanderbilt University, Nashville, TN, USA). Data 
management protocols ensured security (encryption), 
tracking (user identification numbers and audit trails), 
and synchronisation between devices within the cluster 
and with the Research Electronic Data Capture server.
Procedures
For this secondary analysis, we included women who 
died in any of the 44 intervention or control clusters, as 
our primary interest was in measuring the causes and 
circumstances of maternal death.
In a central process at UBC, for all maternal deaths, 
two doctors independently reviewed all trial surveillance 
data and verbal autopsies, and community health worker­
led visit data for intervention clusters. The reviewers’ 
experience was in maternal–fetal medicine (PvD), 
obstetrics (AMA or KA), and obstetric medicine (LAM; 
also an assessor and chapter writer for the UK and 
Ireland Confidential Enquiries into Maternal Death and 
Morbidity). The reviewers were masked to the InterVA­
generated cause of death until the cause of death 
from physician review was established. Cause of death 
was classified according to the nine categories of the 
WHO International Classification of Diseases­Maternal 
Mortality (ICD­MM).10 Disagreement was resolved by 
consensus, involving a third doctor, if necessary. If 
consensus could not be reached, cause of death was that 
assigned by two reviewers who agreed. If no two agreed, 
cause of death was considered undetermined. In India, 
supplementary data from the MNH Registry was used to 
facilitate the physician review of circumstances of death.
For all maternal deaths, the 2012 WHO verbal autopsy, 
a question naire specifically designed by WHO for 
automated processing on the basis of previous validation 
between physician review and causes of death, was 
analysed by the InterVA suite of computer models 
(versions 4 and 5) to generate cause of death categorised 
according to the ICD­MM. InterVA­4 was available at the 
time that the CLIP trials were planned and executed; 
InterVA­5 was included when released during the trials to 
provide the most useful comparisons. The a priori 
probabilities for each of malaria and HIV were set as high 
for Mozambique and low for India and Pakistan. If the 
InterVA cause of death output for a woman gave more 
than one possible cause of death, the one with the highest 
probability was used for comparison with cause of death 
assigned by physician review.
InterVA­5 was published in 2018, to harmonise with 
the new WHO verbal autopsy 2016 standard, following 
updates to the 2012 WHO verbal autopsy based on the 
processing of more than 650 000 verbal autopsy reports 
with InterVA­4.6 Of relevance to this analysis, InterVA­5 
incorporates a novel circumstances of mortality 
categories (COMCAT) analysis,11 with circumstances 
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categorised as traditions, emergencies, recognition, 
resources, health systems, inevitability, and multiple11 
(definitions provided in the panel). In India, where 
additional information was provided by MNH Registry 
data, clinical care was evaluated as part of the physician 
review process to ascertain whether improvements in 
care could be identified that might have made a difference 
to survival outcome (as opposed to good care, with any 
improvements in care identified as unlikely to have made 
a difference to outcome), as undertaken in the UK and 
Ireland Confidential Enquiries into Maternal Deaths and 
Morbidity;4 the results informed a COMCAT assessment 
by physician review, in which inevitability was the 
classification assigned when no improvements in care 
were identified. We present the InterVA­5 COMCAT 
assessment of all three trials and physician review­
generated assessments of the India trial data. A formal 
quali tative analysis of verbal autopsy narratives from all 
three countries is being under taken and a separate 
publication is planned.
Statistical analysis
Descriptive analyses were undertaken, overall and by 
country, to evaluate MMR (maternal deaths per 100 000 
livebirths) and maternal death rate (MDR, as the 
number of maternal deaths per 100 000 identified 
pregnancies); maternal and pregnancy characteristics 
at enrolment (baseline) and associated pregnancy 
outcomes (from trial surveillance); the details of 
maternal deaths (from trial surveillance and verbal 
autopsy forms); and causes of death and, for India only, 
COMCATs, assigned by physician review, InterVA­4, and 
InterVA­5. For MMR and MDR we calculated 95% Wald­
type CIs.
InterVA­4 assignment of hypertensive disorders of 
pregnancy as a cause of death, as a secondary interest of 
our analysis, was compared between intervention and 
control clusters, with multilevel modelling and adjusted 
odds ratios (ORs) with 95% CIs (fixed effects for maternal 
age, parity [nulliparous vs parous], and basic education, 
and random effects for country and cluster). Basic 
education was defined as primary education (country 
specific) and determined from self­reported number of 
years of school attended. Mortality was also compared 
between intervention and control clusters with similar 
adjusted models (excluding random effects for cluster).
The maternal causes of death assigned by physician 
review, InterVA­4, and InterVA­5 were compared 
for overall deaths and by country, according to a 
three­category classification (as per the ICD­MM) of 
direct maternal cause, indirect maternal cause, or 
undetermined; the nine­category ICD­MM classification; 
and a seven­category COMCAT classification (India 
data only). Agreement was estimated with Cohen’s κ 
coefficient with 95% CIs; agreement was considered 
poor for κ values less than 0·40, fair to good for κ values 
in the range 0·40–0·75, and excellent for κ values greater 
than 0·75.12 Analyses were done with R programming 
software (version 3.3.2).
The CLIP trials were approved by the UBC research 
ethics board (H12­03497), and within each country 
(KLE University [MDC/IECHSR/2013­14/A and ICMR 
5/7/859/12­RHN], India; Aga Khan University 
[2590­Obs­ERC­13], Pakistan; and Centro de Investigação 
em Saúde da Manhiça [CIBS­CISM/038/14] and 
Mozambique National Bioethic Committee [219/
CNBS/13], Mozambique). The CONSORT and STROBE 
checklists are in the appendix (pp 3–11).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
Among the 61 988 pregnancies with successful follow­up 
in the CLIP trials, 143 maternal deaths were reported 
(16 deaths in India, 105 in Pakistan, and 22 in Mozambique). 
For 127 (89%) deaths, data were acquired solely in women’s 
communities rather than from facilities. The probability of 
maternal death did not differ in the intervention clusters 
(77 deaths) versus control clusters (66 deaths), adjusted for 
trial setting (country and cluster)  and baseline maternal 
characteristics (age, parity, and basic education; adjusted 
OR 1·05 [95% CI 0·67–1·64], p=0·84).
From the 143 maternal deaths, we calculated an 
overall MMR of 253 (95% CI 212–295) per 100 000 live­
births, and an MDR of 231 (95% CI 193–268) per 
100 000 identified pregnancies, with the lowest MDR 
Panel: Circumstances of mortality categories (COMCAT) 
definitions11
• Traditions: traditional practices or beliefs influenced 
health seeking behaviour and the pathway to death
• Emergencies: sudden, urgent, or unexpected conditions 
leading to death, which probably precluded life-saving 
actions
• Recognition: poor recognition or awareness of serious 
disease, such as symptoms or severity, had a negative 
influence on health seeking behaviour
• Resources: inability to mobilise and use resources, such as 
material, transport, or financial, that hindered access to 
health care
• Health systems: problems in getting health care despite 
accessing health facilities, such as problems related to 
admissions, treatments, and medications
• Inevitability: death occurred in circumstances that could 
not reasonably have been averted, such as in the context 
of old age or recognised terminal conditions
• Multiple: a combination of the other COMCATs affected 
the pathway to death, with no single factor predominant 
at a likelihood of more than 50%
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in India (123 [63–183] per 100 000) and the highest in 
Pakistan (293 [237–349] per 100 000; table 1).
Women who died were young, ranging in median age 
from 21·5 years (IQR 20·0–24·0) in India to 30·0 years 
(25·0–32·0) in Pakistan (table 1). Most women were 
parous, particularly in Pakistan. A basic level of education 
was reported by most women in India, more than half 
in Mozambique, and a minority in Pakistan. All women 
were married in India and Pakistan, but only half 
were married in Mozambique. Generally, women who 
died in India had attended at least one antenatal care 
appointment in the first trimester (gestational weeks 
1–12; ten [63%] of 16 women) and most had received at 
least four routine antenatal care visits. In Pakistan and 
Mozambique, women who died had attended their first 
appointment at a median of 21–22 weeks’ gestation 
(middle of their second trimester), and only about a third 
had received four or more antenatal care visits. Few 
women had attended their first appointment in the first 
trimester (ten [10%] of 105 women in Pakistan and two 
[9%] of 22 in Mozambique). 
Details of maternal deaths were recorded by verbal 
autopsy as early as one week (median 8 days [IQR 3–21]) 
after death in India, to more than 5 months (158 days 
[47–252]) after death in Mozambique (table 1). The verbal 
autopsy respondent differed by country, and was most 
often the husband (widower) in India and the husband’s 
parents (parents­in­law) in Pakistan, with a wide variety of 
respondents in Mozambique.
The frequency with which women had antecedent 
maternal morbidity varied by country. Most of the 
women who died in India had a documented serious 
end­organ complication, followed by around a third of 
the women in Pakistan, and about a quarter of the 
women in Mozambique (table 1). In addition, morbidity 
was defined by having received a potentially life­saving 
intervention, typically cardio pulmonary resuscitation or 
blood transfusion.
Most women died in a health facility, although about a 
third died in transit to a facility in India (table 1). About a 
quarter of women died antepartum and, by definition, 
undelivered. Based on median gestational age at death in 
each country, antepartum deaths typically occurred early 
in the third trimester (India), late preterm (Pakistan), or 
at term (Mozambique). About three­quarters of women 
died post partum, either after late preterm delivery 
(Mozambique) or at term (India and Pakistan). These 
women most frequently died within 24 h post partum, 
although many died more than 1 week after birth. Mode 
of delivery was usually vaginal and at a health facility. 
Among all women who died, stillbirth was frequent, 
particularly in Pakistan and Mozambique, and a fifth of 
babies born alive subsequently died, usually within the 
first 7 days after birth.
Cause of death assigned by physician review was 
informed by next­of­kin narratives (in addition to the 
structured verbal autopsy interview) for all deaths in 
India and Mozambique, and 55 (52%) of 105 deaths 
in Pakistan. In the physician review and InterVA 
assignment of total maternal deaths (n=143) as having 
direct maternal cause, indirect maternal cause, or unde­
termined, deaths were most often attributed to direct 
maternal causes (table 2). This was true overall and 
by country, with the exception of physician review 
assignments in Mozambique, where slightly more 
than half of deaths (12 [55%] of 22) were attributed to 
indirect maternal causes. Expectedly, these deaths in 









Incidence of maternal deaths
MMR, deaths per 100 000 
livebirths
253 (212–295) 145 (74–216) 319 (259–381) 174 (102–247)
MDR, deaths per 100 000 
identified pregnancies
231 (193–268) 123 (63–183) 293 (237–349) 167 (97–237)
Maternal and pregnancy characteristics
Maternal age, years 28·0 (24·5–32·0) 21·5 (20·0–24·0) 30·0 (25·0–32·0) 26·5 (22·3–34·0)
Nulliparous 32 (22%) 7 (44%) 19 (18%) 6 (27%)
Missing 6 (4%) 0 6 (6%) 0
Basic education 37 (26%) 12 (75%) 13 (12%) 12 (55%)
Married 132 (92%) 16 (100%) 105 (100%) 11 (50%)
Gestational age at 
enrolment, weeks
19·8 (14·6–26·4) 11·2 (8·5–13·5) 21·2 (15·9–26·8) 21·7 (17·5–30·5)
Number of routine 
antenatal care visits
3 (1–5) 5 (4–6) 2 (1–4) 0 (0–4)
At least one visit 110 (77%) 16 (100%) 84 (80%) 10 (45%)
At least four visits 55 (38%) 13 (81%) 35 (33%) 7 (32%)
Details of maternal deaths
Latency between death and 
verbal autopsy completion, 
days
62 (33–103) 8 (3–21) 64 (35–100) 158 (47–252)
Respondent for the verbal autopsy
Husband 21 (15%) 8 (50%) 10 (10%) 3 (14%)
Sibling (sister or brother) 22 (15%) 0 19 (18%) 3 (14%)
Sister in-law or 
brother-in-law
25 (17%) 2 (13%) 22 (21%) 1 (5%)
Mother or father 13 (9%) 1 (6%) 8 (8%) 4 (18%)
Mother in-law or 
father-in-law
47 (33%) 3 (19%) 41 (39%)* 3 (14%)
Other (requested to 
specify)
15 (10%) 2 (13%)† 5 (5%)* 8 (36%)‡
Antecedent maternal morbidities documented
One or more serious end-
organ complications
56 (39%) 12 (75%) 38 (36%) 6 (27%)
Seizure 11 (8%) 5 (31%) 5 (5%) 1 (5%)
Stroke 14 (10%) 6 (38%) 6 (6%) 2 (9%)
Coma 10 (7%) 1 (6%) 6 (6%) 3 (14%)
Antepartum 
haemorrhage 
11 (8%) 1 (6%) 9 (9%) 1 (5%)
Disseminated 
intravascular coagulation
5 (3%) 2 (13%) 2 (2%) 1 (5%)
Sepsis 13 (9%) 2 (13%) 8 (8%) 3 (14%)
Fistula 0 0 0 0
(Table 1 continues on next page)
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non­obstetric compli cations among the nine categories 
of the ICD­MM, related primarily to infectious 
diseases (n=9; most commonly HIV [n=2] and 
malaria [n=4]), or cardiac disease (n=3; appendix 
pp 12–14). For the three­category classification of 
maternal cause of death (direct maternal, indirect 
maternal, or undetermined), we observed fair to good 
agreement between physician review and either 
InterVA­4 (κ=0·56 [95% CI 0·43–0·66]) or InterVA­5 
(κ=0·44 [0·30–0·57]), and between InterVA­4 and 
InterVA­5 (κ=0·72 [0·60–0·84]; table 3).
In the ICD­MM classification of specific cause of death, 
the three top causes for overall deaths were the same by 
physician review, InterVA­4, and InterVA­5 (figure). These 
were obstetric haemorrhage (ICD­MM category 3), 
followed by non­obstetric compli cations (ICD­MM 
category 7), and hypertensive disorders (ICD­MM 
category 2). Hypertensive disorders as a cause of death 
(by InterVA­4) did not differ in the intervention clusters 
(13 [17%] of 77 deaths) versus the control clusters (12 [18%] 
of 66 deaths; OR 0·93 [95% CI 0·46–1·89]; p=0·84). 
Attribution to obstetric haemorrhage varied more 
between methods (physician review, 38 [27%] deaths; 
InterVA­4, 69 [48%] deaths; and InterVA­5, 82 [57%] 
deaths) than did attribution to non­obstetric causes 
(physician review, 39 [27%] deaths; InterVA­4, 37 [26%] 
deaths; and InterVA­5, 28 [20%] deaths), or hypertensive 
disorders (physician review, 23 [16%] deaths; InterVA­4, 
25 [17%] deaths; and InterVA­5, 24 [17%] deaths; table 2, 
figure). Few maternal deaths (<5% and often <1%) 
were attributed to pregnancy­related infection, abortive 
outcomes, unanticipated complications of manage ment, 
or coincidental causes (figure, table 2). A small proportion 
of all maternal causes of death were unknown or 
undetermined (16 [11%] deaths assigned by physician 
review, six [4%] by InterVA­4, and four [3%] by InterVA­5). 
Agreement between the cause of death methods for the 
nine ICD­MM categories was fair for physician review 
versus InterVA­4, poor for physician review versus 
InterVA­5, and good for InterVA­4 versus InterVA­5 
(table 3); similar results were observed by country 
(appendix p 15). Physician review identified that in cases 
of shock, women could be assigned by InterVA as having 
obstetric haemorrhage without any evidence of bleeding 
(31 ([22%] and 44 [31%] additional cases of obstetric 
haemorrhage by InterVA­4 and InterVA­5, respectively). 
By physician review, these cases were distributed between 
other causes of death excluding hypertension.
For circumstances of death, InterVA­5 most commonly 
assigned the COMCAT classifications of emergencies 
(68 [48%] of 143 deaths) and health systems (62 [43%] 
deaths); whereas, few maternal deaths were assigned 
to traditions, recognition, or multiple circumstances. 
By physician review (possible only in India), health 
systems (seven [44%] of 16 deaths) and inevitability 
(five [31%] deaths) were the most common circumstances 









(Continued from previous page)
Life-saving interventions 
given during pregnancy
40 (28%) 9 (56%) 28 (27%) 3 (14%)
Cardiopulmonary 
resuscitation
24 (17%) 3 (19%) 19 (18%) 2 (9%) 
Dialysis 3 (2%) 1 (6%) 2 (2%) 0
Mechanical ventilation 8 (6%) 3 (19%) 3 (3%) 2 (9%) 
Blood transfusion 22 (15%) 6 (38%) 16 (15%) 0
Intervention for major 
post-partum 
haemorrhage
5 (3%) 2 (13%) 2 (2%) 1 (5%) 
Missing 16 (11%) 0 14 (13%) 2 (9%) 
Location of death§
Home 24 (17%) 1 (6%) 19 (18%) 4 (18%)
In transit to facility 16 (11%) 5 (31%) 10 (10%) 1 (5%)
Health facility 103 (72%) 10 (63%) 76 (72%) 17 (77%)
Timing of death§
Antepartum 38 (27%) 5 (31%) 28 (27%) 5 (23%)
Post partum 105 (73%) 11 (69%) 77 (73%) 17 (77%)
For women who died antepartum
Gestational age at death, 
weeks§
34·5 (30·8–38·3) 30·0 (28·5–33·5) 35·5 (32·3–39·0) 38·0 (28·0–39·0)
For women who died post partum
Gestational age at delivery, 
weeks
38·0 (34·0–40·0) 37·0 (31·0–41·0) 38·0 (34·5–40·0) 35·0 (34·5–41·0)
Timing of death post partum§
<24 h 59/105 (56%) 6/11 (55%) 46/77 (60%) 7/17 (41%)
1–6 days 17/105 (16%) 2/11 (18%) 12/77 (16%) 3/17 (18%)
1–6 weeks 24/105 (23%) 3/11 (27%) 15/77 (19%) 6/17 (35%)
Missing 5/105 (5%) 0 4/77 (5%) 1/17 (6%)
Mode of delivery§
Caesarean 38/105 (36%) 4/11 (36%) 26/77 (34%) 8/17 (47%)
Vaginal birth 67/105 (64%) 7/11 (64%) 51/77 (66%) 9/17 (53%)
Location of birth§
Home 16/105 (15%) 1/11 (9%) 11/77 (14%) 4/17 (24%)
Health facility 89/105 (85%) 10/11 (91%) 66/77 (86%) 13/17 (76%)
In transit 0 0 0 0
Pregnancy outcome for all women
Stillbirth 28 (20%) 1 (6%) 20 (19%) 7 (32%)
Early neonatal death 
(≤7 days after birth)
19 (13%) 2 (13%) 14 (13%) 3 (14%)
Late neonatal death 
(>7 days after birth)
4 (3%) 0 3 (3%) 1 (5%)
Survived follow-up 92 (64%) 13 (81%) 68 (65%) 11 (50%)
Data are n (%), n/N (%), or median (IQR); values in parentheses for MMR and MDR are 95% CIs. Percentages might not 
always add to 100% due to rounding. CLIP=Community-Level Interventions for Pre-eclampsia. MMR=maternal mortality 
ratio. MDR=maternal death rate. *The other respondents in Pakistan were aunt (n=3), grandparent (n=1), or child (n=1); all 
of the mother-in-law or father-in-law respondents were mothers-in-law. †The other respondents in India were 
grandparent (n=2). ‡The other respondents in Mozambique were aunt (n=1), child (n=2), child-in-law (n=1), grandparent 
(n=1), a neighbour (n=1), or a so-called rival (co-spouse or other sexual partner of the father of the pregnancy; n=2). 
§These data were taken from verbal autopsies as the information was not available from trial surveillance reports.
Table 1: Baseline maternal characteristics, CLIP intervention, and pregnancy outcomes for 143 maternal 
deaths in the CLIP trials
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and InterVA­5 for COMCAT (India data only) was poor 
(κ=0·04 [95% CI 0·00–0·15).
During physician review of maternal deaths in India, 
distinguishing between the COMCATs of emergencies 
and inevitability was difficult without direct review of 
health records to understand quality of care. Physician 
review of summary data in the MNH Registry identified 
six of the 16 maternal deaths for which improvements 
in care might have made a difference to outcome. Five 
were classified under health systems circumstances, 
related to suboptimal facility care (n=3 for hypertensive 
pregnancies, either failure to administer antihyper­
tensives for severe hypertension [n=2] or to initiate birth 
for pre­eclampsia at term [n=1]; and n=2 for obstetric 
haemorrhage when no intervention for the haemorrhage 
was offered). In one case of cardiovascular collapse in 
transit to facility (deemed an emergency), no cardio­
pulmonary resuscitation was attempted.
Although quality of care could not be assessed 
formally in Pakistan or Mozambique due to the scarcity 
of detailed information from health facilities, the 
narratives from next of kin did highlight some of the 
health systems failures identified by the InterVA­5 
COMCAT analysis of deaths overall, and by physician 
review in India. Reviewers noted several instances in 
which the woman’s relatives were asked to arrange blood 
products for transfusion, even during resuscitation for 
obstetric haemorrhage. In addition, reviewers noted 
several instances in which the woman was ill and 





Direct maternal cause 88 (62%) 100 (70%) 110 (77%)
Indirect maternal cause 39 (27%) 37 (26%) 28 (20%)
Undetermined cause 16 (11%) 6 (4%) 5 (3%)
Nine-category classification (ICD-MM)
(1) Abortive outcomes 1 (1%) 0 1 (1%)
(2) Hypertensive disorders 23 (16%) 25 (17%) 24 (17%)
(3) Obstetric haemorrhage 38 (27%) 69 (48%) 82 (57%)
(4) Pregnancy-related 
infection
6 (4%) 2 (1%) 0
(5) Other obstetric 
complications




Uterine inversion or 
rupture
2/16 0 1/3
Suicide 2/16 1/4 1/3
Obstructed labour 0 3/4 1/3
Other* 4/16 0 0
(6) Unanticipated 
complications of clinical 
management
4 (3%) 0 0
(7) Non-obstetric 
complications
39 (27%) 37 (26%) 28 (20%)
Infectious disease 26/39 28/37 20/28
Respiratory 9 11 9
Gastrointestinal 3 1 0
Malaria 5 4 1
HIV 2 8 7
Tuberculosis 2 3 1
Other† 5 1 2
Cardiac disease 10/39 3/37 4/28
Liver disease 2/39 3/37 2/28
Other‡ 1/39 3/37 2/28
(8) Unknown or 
undetermined
16 (11%) 6 (4%) 4 (3%)
(9) Coincidental causes 0 0 1 (1%)
(Table 2 continues in next column)
κ (95% CI)*
Three-category classification (ICD-MM)
Physician review versus InterVA-4 0·56 (0·43–0·66)
Physician review versus InterVA-5 0·44 (0·30–0·57)
InterVA-4 versus InterVA-5 0·72 (0·60–0·84)
Nine-category classification (ICD-MM)
Physician review versus InterVA-4 0·48 (0·38–0·58)
Physician review versus InterVA-5 0·36 (0·27–0·46)
InterVA-4 versus InterVA-5 0·69 (0·59–0·79)
ICD-MM=International Classification of Diseases-Maternal Mortality. 
InterVA=interpreting verbal autopsy. *A κ statistic of less than 0·40 was 
considered poor agreement, 0·40–0·75 fair to good agreement, and greater 
than 0·75 excellent agreement.
Table 3: Cohen’s κ statistics for agreement between methods of 




(Continued from previous column)
COMCAT§
Traditions 0¶ NA 1/143 (1%)
Emergencies 2/16 (13%)¶ NA 68/143 (48%)
Recognition 2/16 (13%)¶ NA 1/143 (1%)
Resources 0 NA 9/143 (6%)
Health systems 7/16 (44%)¶ NA 62/143 (43%)
Inevitability 5/16 (31%)¶ NA 0
Multiple 0¶ NA 2/143 (1%)
Data are numbers of women and percentages. Percentages might not always add to 
100% due to rounding. COMCAT=circumstances of mortality categories. 
ICD-MM=International Classification of Diseases-Maternal Mortality. 
InterVA=interpreting verbal autopsy. NA=not applicable. *Other obstetric 
complications were amniotic fluid embolism (n=1), peripartum cardiomyopathy 
(n=1), complications of intrauterine fetal demise (n=1), and disseminated 
intravascular coagulation (n=1). †Other infections were meningitis (n=2), tetanus 
(n=1), hepatitis (n=1), measles (n=1), and infections not otherwise specified (n=3). 
‡Other non-obstetric causes were stroke (n=1), breast neoplasm (n=1), asthma 
(n=2), and chronic obstructive pulmonary disease (n=2). §COMCAT definitions are 
provided in the panel. ¶India only.
Table 2: Maternal causes of death as determined by InterVA and 
physician review for overall deaths (N=143)
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were deemed too ill for that facility, refused assessment 
or treatment, and advised to seek help at another facility, 
without transport assistance. Publication of the complete 
verbal autopsy analysis is planned.
Discussion
For the 143 maternal deaths (MMR 253 [95% CI 212–295] 
per 100 000 livebirths) in the CLIP trials in India, Pakistan, 
and Mozambique, we found that physician review and 
the computer algorithms of InterVA­4 and InterVA­5 had 
high public health equivalence, revealing the same top 
three maternal causes of death: obstetric haemorrhage, 
non­obstetric causes, and hypertensive disorders of 
pregnancy. However, attribution to each cause of death 
varied by method; of the three methods, InterVA­5 was 
most likely to assign obstetric haemorrhage and least 
likely to assign non­obstetric causes as a cause of death. 
Agreement for physician review versus InterVA­4 was 
better than for physician review versus InterVA­5. Both 
the physician review and InterVA­5 COMCAT analyses 
identified health systems circum stances as underlying 
more than 40% of maternal deaths, but physician review 
also commonly identified inevitability of circumstance, 
whereas emergency circum stances were identified the 
most by InterVA­5.
Our findings suggest that for public health planning 
and policy aimed at reducing maternal death, InterVA­4 
is a reasonable alternative to physician review; how­
ever, obstetric haemorrhage might be over­represented, 
particularly if women show signs of shock without 
evidence of bleeding. Physician review was informed 
by next­of­kin narratives; developments in software 
interpretation of free text might lead to further 
improvements in InterVA algorithm performance. 
InterVA­5 performed poorly for maternal cause of death, 
particularly in identifying non­obstetric causes. This 
finding might be increasingly relevant as countries 
move through stages of obstetric transition and indirect 
causes of death increase in frequency.13
The novel InterVA­5 COMCAT analysis of maternal 
deaths did not highlight delays in care (in obstetric 
care­seeking or in reaching an appropriate obstetric 
facility, commonly referred to as first and second 
delays, respectively14); traditions, recognition, and 
resources were indicated to be unimportant for most 
women in the events leading to their deaths. Furthermore, 
few women were identified to have multiple underly­
ing circumstances. These insights emphasise the 
importance of delays in receiving quality care (the so­
called third delay14), especially in continuity of care, as 
being modifiable contributors to maternal deaths; if 
addressed, outcomes should improve. Additionally, our 
findings suggest that for maternal death specifically, 
further work might be required to distinguish between 
emergencies (for which outcomes would be avoidable 
only through prevention, rather than treat ment) and 
inevitability (particularly for women offered good care 
who, nevertheless, did not avoid death).
Figure: Maternal causes of death according to physician review, InterVA-4, and InterVA-5 (N=143)



































































(5) Other obstetric complications
(8) Unknown or undetermined
(3) Obstetric haemorrhage
(6) Unanticpated complications of management
(9) Coincidental causes
International Classification of Diseases-Maternal Mortality category
Physician 
review
InterVA-4 InterVA-5 Physician 
review
InterVA-4 InterVA-5 Physician 
review
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To our knowledge, this study provides the first 
comparison of maternal causes of death by physician 
review, InterVA­4, and InterVA­5, and of COMCAT 
analyses by physician review and InterVA­5. One 
published comparison of InterVA­4 and InterVA­5 
focused on HIV and excluded maternal deaths.15 A 
second publication evaluated the causes of all deaths in 
adults and children, comparing physician­assigned cause 
of death at tertiary hospitals involved in final care with 
InterVA­4 and InterVA­5, which found high concordance 
(eg, InterVA­5 correlation coefficient of 0·86 [0·79–0·93] 
for adults).6
InterVA­4 has been compared with physician review for 
deaths in general16–19 and for maternal death specifically.20 
In Africa and Asia among adults or the general 
population, concordance between physician review and 
InterVA­4 has been variably reported, as high (≥80%)17,18 
or not.16,19,21 Among 86 maternal deaths analysed at the 
health­facility level in Malawi, fair to good agreement 
was reported between an expert physician review panel 
and InterVA­4 for ICD­MM categories 1–7 (Cohen’s 
κ=0·66), although the expert physician review panel 
assigned cause of death as unspecified more often than 
both InterVA­4 and InterVA­5.20 In that analysis, the 
top four assigned direct maternal causes of death for 
expert physician review and InterVA­4 were obstetric 
haemorrhage (34% vs 30%), pregnancy­related infections 
(14% vs 17%), hypertensive disorders (12% vs 16%), and 
pregnancy with abortive outcomes (14% vs 15%). Similar 
to the Malawi study, agreement between physician review 
and InterVA­4 in our analysis was fair to good, and 
physician review identified unknown or indeterminate 
cause of death more frequently than InterVA­4; however, 
our κ value was lower (0·48 vs 0·6620), which might have 
been due to our assessment of deaths in three countries 
(rather than one), or that most of our data (89%) for 
physician review was from the community (rather than 
from a single health facility).
Strengths of our study include a relatively large sample 
of deaths, representation of urban and rural settings 
in south Asia and sub­Saharan Africa, and use of data 
from communities, making our results generalisable to 
where there is the greatest need for computerised cause 
of death analysis of verbal autopsies. We compared 
physician review and both InterVA­4 and InterVA­5 
computerised algorithms for cause of death and 
COMCAT.
Limitations include those of the verbal autopsy itself, 
which has questions lacking clarity of purpose, such 
as the needed or received designation for medication, 
rather than needed but unavailable or not received, 
meaning the possibility for improvements in care cannot 
be determined. Physician review was done by a central 
team familiar with local contexts, but from none of the 
CLIP countries. Social factors were considered in this 
review; however, a social autopsy or diagnosis was not 
done, based on availability of resources. A verbal autopsy 
narrative was available for about two­thirds of maternal 
deaths in Pakistan (65% of deaths overall), and narratives 
in Mozambique were limited in detail. Although CLIP 
data forms were available for physician review, the lack of 
comprehensive, detailed verbal autopsy narratives for all 
deaths might have compromised cause of death 
assignment in Pakistan and Mozambique, where quality 
of care could not be evaluated. The lack of detailed verbal 
autopsy reports was compounded by limited detail in 
women’s health records in these settings. The between­
country differences in respondents and verbal autopsy 
timing might have had an effect on responses, but the 
top causes of death and proportion of direct maternal 
deaths were similar; we had insufficient power to 
examine these differences by country. Finally, we were 
not able to identify how weights in the probabilistic 
model for InterVA­5 differed from InterVA­4, because 
neither demographic health survey data nor health 
facility records were available to us.
Our findings suggest that InterVA­4, not InterVA­5, 
should be used to ascertain maternal cause of death, 
particularly given the global rise in non­obstetric maternal 
deaths,22 and to assist in reaching WHO’s global standard 
of registering at least 50% of deaths in com munities.23 
Further work is required to refine InterVA­5 regarding 
assignment of obstetric haemorrhage and non­obstetric 
causes of death and COMCAT analysis, and to identify 
opportunities for improving maternal outcomes.
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